APLM

APOLLOMICS INC

• Benzinga·04/27 12:06

  Apollomics FY EPS $(7.57) Up From $(52.80) YoY, Sales $8.500M

• Dow Jones·04/27 12:03

  *Apollomics 2025 Research and Development Expenses About $5.5M >APLM

• Dow Jones·04/27 12:03

  *Apollomics 2025 Loss/Shr $7.57 >APLM

• Dow Jones·04/27 12:02

  *Apollomics 2025 Rev $8.5M >APLM

• Dow Jones·04/27 12:00

  Press Release: Apollomics Reports Full Year 2025 -2-

• Dow Jones·04/27 12:00

  Press Release: Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress

• PUBT·04/24 20:25

  Apollomics FY25 net loss narrows 79.7% to USD 10.9 million; revenue rises to USD 8.5 million

• Reuters·04/01 20:52

  Apollomics enters USD 2 million unsecured convertible note with CEO Chen

• Seeking Alpha·04/01 12:53

  Apollomics secures $2M bridge financing from CEO

• NASDAQ·04/01 11:40

  Apollomics Secures $2 Million Bridge Financing To Support Clinical Programs

• Benzinga·04/01 11:11

  Apollomics Enters Into $2M Unsecured Convertible Promissory Note With Its Chairman And CEO Hung-Wen Chen On March 30

• Reuters·04/01 11:04

  Apollomics secures $2 million 0%-interest convertible note from CEO Chen

• Reuters·04/01 11:00

  APOLLOMICS INC. ANNOUNCES $2.0 MILLION BRIDGE FINANCING

• Dow Jones·04/01 11:00

  Press Release: Apollomics Inc. Announces $2.0 Million Bridge Financing

• Benzinga·03/30 17:05

  12 Health Care Stocks Moving In Monday's Intraday Session